Exhibit 99.1 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 9, 2024 -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of ...